Reduction of immunosuppression for transplant-associated skin cancer: Thresholds and risks

C. C. Otley, M. D. Griffin, M. R. Charlton, Brooks Sayre Edwards, M. Neuburg, T. Stasko

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Although evidence supports the efficacy of reducing immunosuppression for transplant-associated skin cancer, clinical thresholds for and risks associated with reduction are not well defined. Objectives: In this study, experienced transplant physicians were surveyed regarding appropriate thresholds for consideration of reduction of immunosuppression and the likelihood of rejection and allograft compromise associated with various levels of reduction. Patients and methods: Fifty-two transplant physicians reviewed 13 hypothetical patient scenarios with graduated morbidity and mortality risk and provided opinions on the degree of reduction of immunosuppression that was warranted and the risks associated with various degrees of reduction. Results: Renal, liver and cardiac transplant physicians generally concurred on the level of reduction of immunosuppression warranted by various degrees of skin cancer. As morbidity and mortality from skin cancer increased, physicians were more likely to accept risk to allograft function from more aggressive reduction. Conclusions: Reduction of immunosuppression is considered a reasonable adjuvant strategy in recipients of solid organ transplants who have substantial morbidity and mortality risk from skin cancer. Physicians are willing to accept an increased risk of allograft compromise when confronted by severe or extensive skin cancer. Further research is needed to define the precise correlation among levels of reduction of immunosuppression, therapeutic efficacy, and concomitant risks.

Original languageEnglish (US)
Pages (from-to)1183-1188
Number of pages6
JournalBritish Journal of Dermatology
Volume157
Issue number6
DOIs
StatePublished - Dec 2007

Fingerprint

Skin Neoplasms
Immunosuppression
Transplants
Physicians
Allografts
Morbidity
Mortality
Kidney
Liver
Research

Keywords

  • Allograft compromise
  • Immunosuppression
  • Skin cancer
  • Transplant

ASJC Scopus subject areas

  • Dermatology

Cite this

Reduction of immunosuppression for transplant-associated skin cancer : Thresholds and risks. / Otley, C. C.; Griffin, M. D.; Charlton, M. R.; Edwards, Brooks Sayre; Neuburg, M.; Stasko, T.

In: British Journal of Dermatology, Vol. 157, No. 6, 12.2007, p. 1183-1188.

Research output: Contribution to journalArticle

Otley, C. C. ; Griffin, M. D. ; Charlton, M. R. ; Edwards, Brooks Sayre ; Neuburg, M. ; Stasko, T. / Reduction of immunosuppression for transplant-associated skin cancer : Thresholds and risks. In: British Journal of Dermatology. 2007 ; Vol. 157, No. 6. pp. 1183-1188.
@article{8b2c07817b3e437799559ff7cc7fe745,
title = "Reduction of immunosuppression for transplant-associated skin cancer: Thresholds and risks",
abstract = "Background: Although evidence supports the efficacy of reducing immunosuppression for transplant-associated skin cancer, clinical thresholds for and risks associated with reduction are not well defined. Objectives: In this study, experienced transplant physicians were surveyed regarding appropriate thresholds for consideration of reduction of immunosuppression and the likelihood of rejection and allograft compromise associated with various levels of reduction. Patients and methods: Fifty-two transplant physicians reviewed 13 hypothetical patient scenarios with graduated morbidity and mortality risk and provided opinions on the degree of reduction of immunosuppression that was warranted and the risks associated with various degrees of reduction. Results: Renal, liver and cardiac transplant physicians generally concurred on the level of reduction of immunosuppression warranted by various degrees of skin cancer. As morbidity and mortality from skin cancer increased, physicians were more likely to accept risk to allograft function from more aggressive reduction. Conclusions: Reduction of immunosuppression is considered a reasonable adjuvant strategy in recipients of solid organ transplants who have substantial morbidity and mortality risk from skin cancer. Physicians are willing to accept an increased risk of allograft compromise when confronted by severe or extensive skin cancer. Further research is needed to define the precise correlation among levels of reduction of immunosuppression, therapeutic efficacy, and concomitant risks.",
keywords = "Allograft compromise, Immunosuppression, Skin cancer, Transplant",
author = "Otley, {C. C.} and Griffin, {M. D.} and Charlton, {M. R.} and Edwards, {Brooks Sayre} and M. Neuburg and T. Stasko",
year = "2007",
month = "12",
doi = "10.1111/j.1365-2133.2007.08203.x",
language = "English (US)",
volume = "157",
pages = "1183--1188",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Reduction of immunosuppression for transplant-associated skin cancer

T2 - Thresholds and risks

AU - Otley, C. C.

AU - Griffin, M. D.

AU - Charlton, M. R.

AU - Edwards, Brooks Sayre

AU - Neuburg, M.

AU - Stasko, T.

PY - 2007/12

Y1 - 2007/12

N2 - Background: Although evidence supports the efficacy of reducing immunosuppression for transplant-associated skin cancer, clinical thresholds for and risks associated with reduction are not well defined. Objectives: In this study, experienced transplant physicians were surveyed regarding appropriate thresholds for consideration of reduction of immunosuppression and the likelihood of rejection and allograft compromise associated with various levels of reduction. Patients and methods: Fifty-two transplant physicians reviewed 13 hypothetical patient scenarios with graduated morbidity and mortality risk and provided opinions on the degree of reduction of immunosuppression that was warranted and the risks associated with various degrees of reduction. Results: Renal, liver and cardiac transplant physicians generally concurred on the level of reduction of immunosuppression warranted by various degrees of skin cancer. As morbidity and mortality from skin cancer increased, physicians were more likely to accept risk to allograft function from more aggressive reduction. Conclusions: Reduction of immunosuppression is considered a reasonable adjuvant strategy in recipients of solid organ transplants who have substantial morbidity and mortality risk from skin cancer. Physicians are willing to accept an increased risk of allograft compromise when confronted by severe or extensive skin cancer. Further research is needed to define the precise correlation among levels of reduction of immunosuppression, therapeutic efficacy, and concomitant risks.

AB - Background: Although evidence supports the efficacy of reducing immunosuppression for transplant-associated skin cancer, clinical thresholds for and risks associated with reduction are not well defined. Objectives: In this study, experienced transplant physicians were surveyed regarding appropriate thresholds for consideration of reduction of immunosuppression and the likelihood of rejection and allograft compromise associated with various levels of reduction. Patients and methods: Fifty-two transplant physicians reviewed 13 hypothetical patient scenarios with graduated morbidity and mortality risk and provided opinions on the degree of reduction of immunosuppression that was warranted and the risks associated with various degrees of reduction. Results: Renal, liver and cardiac transplant physicians generally concurred on the level of reduction of immunosuppression warranted by various degrees of skin cancer. As morbidity and mortality from skin cancer increased, physicians were more likely to accept risk to allograft function from more aggressive reduction. Conclusions: Reduction of immunosuppression is considered a reasonable adjuvant strategy in recipients of solid organ transplants who have substantial morbidity and mortality risk from skin cancer. Physicians are willing to accept an increased risk of allograft compromise when confronted by severe or extensive skin cancer. Further research is needed to define the precise correlation among levels of reduction of immunosuppression, therapeutic efficacy, and concomitant risks.

KW - Allograft compromise

KW - Immunosuppression

KW - Skin cancer

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=36148934968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148934968&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2133.2007.08203.x

DO - 10.1111/j.1365-2133.2007.08203.x

M3 - Article

C2 - 17916206

AN - SCOPUS:36148934968

VL - 157

SP - 1183

EP - 1188

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 6

ER -